Andrew Horwitz I joined the synthetic biology revolution in mid-2011, right before the sector imploded (Figure 1). The survivors, including my employer at the time, Amyris, beat a retreat from biofuels to smaller volume/higher margin opportunities, e.g. flavors and fragrances, cosmetics and nutraceuticals. For some of my colleagues, transitioning from…
